Induction Chemotherapy Plus Simultaneous Modulated Accelerated Radiation Therapy in Non-operative Hypopharyngeal and Supraglottic Laryngeal Squamous Cell Carcinoma: Long-Term Outcome of a Prospective Phase 2 Study

• DOI: 10.3389/fonc.2021.637978
• Publication Date: 2021-03-12T15:49:27Z
• Authors: Boning Cai; Lingling Meng; Jingzi Mo; Shouping Xu; Baolin Qu; Fang Liu; Lin Ma
• Keywords: Mucositis; Hypopharyngeal cancer; Regimen; Induction chemotherapy; Sore throat

Background: To evaluate the toxicities and long-term outcomes of induction chemotherapy (ICT) plus simultaneous modulated accelerated radiation therapy (SMART) in non-operative hypopharyngeal supraglottic laryngeal squamous cell carcinoma (SCCH/L). Materials Methods: This was a prospective phase 2 study. Patients diagnosed with SCCH/L, aged from 18 to 75, staged III IVB accordance AJCC 2010 criteria, refusing surgery were eligible. The patients treated 2–3 cycles docetaxel-cisplatin-based ICT SMART combined cisplatin-based concurrent chemotherapy. prescription dose primary tumor metastatic nodes 69 Gy 30 fractions. Acute late assessed according established Radiation Therapy Oncology Group/European Organization for Research Treatment Cancer (RTOG/EORTC) analyzed. Results: Between February 2013 June 2015, 55 newly SCCH/L enrolled. No grade or worse acute xerostomia noted. incidences 3 dermatitis, oral mucositis, pharyngoesophagitis 12.7, 3.6, 12.7%, respectively. median follow-up time 48 months (range 5.5–74 months). main toxicity hoarseness sore throat, an incidence 32.7%. 5-year functional larynx-preservation survival 51.5%. 3- locoregional control overall 58.2, 51.5, 63.6, 54.1%, Conclusions: regimen Gy/30 F treatment demonstrated acceptable severe toxicity, satisfactory outcomes, function preservation.